MariMed Inc. (MRMD) stock
MRMDOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$0.06−0.00 (-3.39%)
Close on Oct 19, 2026Market cap $22.78MP/E –Yield –
MariMed ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
MariMed's ebitda for the twelve months ending Jun 30, 2026 was $6.29M, down 20.1% year over year. For fiscal 2025 it was $5.29M, down 49.7% from the year before. The highest annual figure on record is $23.80M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.29M | -49.7% |
| FY2024 | Dec 31, 2024 | $10.52M | -47.2% |
| FY2023 | Dec 31, 2023 | $19.93M | -16.2% |
| FY2022 | Dec 31, 2022 | $23.80M | +45.7% |
| FY2020 | Dec 31, 2020 | $16.33M | – |
| FY2019 | Dec 31, 2019 | -$40.53M | – |
| FY2018 | Dec 31, 2018 | -$4.70M | -1057.5% |
| FY2017 | Dec 31, 2017 | $490.65K | -52.9% |
| FY2016 | Dec 31, 2016 | $1.04M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.75M | -12.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.28M | +154.0% |
| Q4 FY2025 | Dec 31, 2025 | -$2.45M | -453.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.71M | +18.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.13M | +5.6% |
| Q1 FY2025 | Mar 31, 2025 | $897.00K | -77.3% |
| Q4 FY2024 | Dec 31, 2024 | $693.00K | -83.2% |
| Q3 FY2024 | Sep 30, 2024 | $3.15M | -35.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.96M | -38.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.96M | -35.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.12M | +1.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.88M | -26.6% |
| Q2 FY2023 | Jun 30, 2023 | $4.81M | -10.0% |
| Q1 FY2023 | Mar 31, 2023 | $6.12M | -21.0% |
| Q4 FY2022 | Dec 31, 2022 | $4.05M | -46.0% |
| Q3 FY2022 | Sep 30, 2022 | $6.65M | -21.7% |
| Q2 FY2022 | Jun 30, 2022 | $5.35M | +39.5% |
| Q1 FY2022 | Mar 31, 2022 | $7.75M | +207.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.50M | +402.9% |
| Q4 FY2020 | Dec 31, 2020 | $8.50M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.83M | +219.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.52M | -55.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$47.34M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.20M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.60M | +812.4% |
| Q1 FY2019 | Mar 31, 2019 | -$4.28K | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$548.99K | -241.8% |
| Q2 FY2018 | Jun 30, 2018 | $614.04K | -11.6% |
| Q1 FY2018 | Mar 31, 2018 | -$240.64K | -180.6% |
| Q4 FY2017 | Dec 31, 2017 | -$889.69K | -225.3% |
| Q3 FY2017 | Sep 30, 2017 | $387.26K | +218.8% |
| Q2 FY2017 | Jun 30, 2017 | $694.70K | +327.6% |
| Q1 FY2017 | Mar 31, 2017 | $298.38K | – |
| Q4 FY2016 | Dec 31, 2016 | $710.16K | – |
| Q3 FY2016 | Sep 30, 2016 | $121.46K | – |
| Q2 FY2016 | Jun 30, 2016 | $162.45K | – |
See a number that looks wrong?